AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules

Why It Matters

Modernizing post‑approval rules could accelerate U.S. reshoring, strengthening supply‑chain resilience and cutting time‑to‑market for biologics. The change would also lower compliance costs for both innovator and generic manufacturers.

Key Takeaways

• Pharma seeks to separate inspections from approval filings
• Calls to modernize 1990s SUPAC guidance
• Goal: accelerate reshoring of biologics manufacturing
• Propose risk‑based, remote assessments for facility changes
• Off‑patent groups back flexible post‑approval processes

Pulse Analysis

The FDA’s post‑approval change regime, anchored in the late‑1990s SUPAC guidance, applies a one‑size‑fits‑all approach to biologics and small‑molecule drugs. Under current rules, even routine site transfers trigger prior‑approval supplements that can take months to clear, creating a bottleneck for companies eager to relocate manufacturing domestically. This rigidity hampers the industry’s broader reshoring agenda, which has gained momentum amid supply‑chain concerns and recent government incentives for U.S. drug production.

At a recent PreCheck meeting, senior regulators from AbbVie, Amgen, Eli Lilly and other majors pressed the agency to decouple facility inspections from the marketing‑authorization filing process and to adopt a risk‑based, data‑driven model for post‑approval changes. They highlighted that many biologics, such as monoclonal antibodies, now have mature, well‑characterized processes that could be evaluated through remote assessments and historical inspection records. By shifting from a prescriptive to a performance‑based framework, the FDA could allocate inspection resources to higher‑risk innovations while streamlining routine site moves.

If the FDA embraces these recommendations, the impact would ripple across the pharmaceutical ecosystem. Faster, less costly facility transfers would encourage manufacturers to bring production back to the United States, bolstering domestic supply‑chain resilience and creating high‑skill jobs. Generic and biosimilar producers, represented by the Association for Accessible Medicines, stand to benefit from broader SUPAC applicability, reducing barriers for off‑patent drugs. Ultimately, a modernized post‑approval regime could accelerate the delivery of new therapies, lower drug costs, and align regulatory oversight with contemporary manufacturing technologies.